SCHEMBL3017281

SCHEMBL3017281

Cc1cc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)c(C)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
GBA1 P04062 2/20 0.39
CNR1 P21554 3/20 0.37
MAPK1 P28482 3/20 0.36
LMNA P02545 3/20 0.36
MAPT P10636 2/20 0.36
USP2 O75604 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
RECQL P46063 1/20 0.36
HSD17B10 Q99714 1/20 0.36
HTT P42858 4/20 0.36
KDM4E B2RXH2 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
POLB P06746 1/20 0.36
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
TSHR P16473 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014213 0.91 KMT2A (0.43) ALDH1A1SMN1; SMN2L3MBTL1GBA1CNR1
SCHEMBL3011003 0.91 POLB (0.46) ALDH1A1SMN1; SMN2L3MBTL1GBA1MAPK1
SCHEMBL3015347 0.90 LMNA (0.45) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3013725 0.89 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2L3MBTL1GBA1CNR1
SCHEMBL3010162 0.88 SMN1; SMN2 (0.46) ALDH1A1SMN1; SMN2L3MBTL1MAPK1MAPT
SCHEMBL3013533 0.88 SMN1; SMN2 (0.47) ALDH1A1SMN1; SMN2L3MBTL1GBA1LMNA
SCHEMBL3013468 0.88 HTT (0.45) ALDH1A1SMN1; SMN2L3MBTL1GBA1MAPK1
SCHEMBL3020591 0.86 NPSR1 (0.48) ALDH1A1MAPK1LMNAMAPTMEN1
SCHEMBL3018162 0.86 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2L3MBTL1GBA1CNR1
SCHEMBL3009591 0.85 LPAR1 (0.42) SMN1; SMN2CNR1MAPK1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA ALDH1A1 3510/4885SMN1; SMN2 1/4885L3MBTL1 1847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.